Melophit 2 Tablet contains Melphalan 2mg, a well-established alkylating agent used in oncology for the treatment of multiple myeloma and selected solid tumors such as ovarian cancer. It plays a key role in chemotherapy protocols aimed at controlling malignant cell proliferation and disease progression.
Melphalan works by cross-linking DNA strands in rapidly dividing cancer cells, thereby inhibiting DNA replication and inducing cell death. This cytotoxic action makes it effective in reducing tumor burden when used under strict medical supervision as part of combination or maintenance chemotherapy regimens.
For distributors and healthcare suppliers, Melophit 2 Tablet is a specialty oncology product, primarily utilized in cancer hospitals, oncology clinics, and tertiary care centers. The consistent requirement for oral chemotherapy agents in long-term cancer management ensures a stable and specialized demand.
Adding Melophit 2 Tablet to your oncology and anticancer therapy segment creates opportunities in hospital supply chains, specialty pharmacies, export markets, and third-party manufacturing. Its established clinical role, controlled usage, and importance in cancer treatment protocols make it a critical product within pharmaceutical oncology portfolios.